淮安市第一人民医院
Huai'an First People's Hospital
在本站收录的 61 种疾病中,这家医院列在其中 15 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
淮安市第一人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma1 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma20 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma6 篇牵头论文
- 胃癌Stomach cancer13 篇牵头论文
- 肺癌Lung cancer19 篇牵头论文
- 胶质瘤Glioma5 篇牵头论文
- 肝母细胞瘤Hepatoblastoma0 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma3 篇牵头论文
- 骨肉瘤Osteosarcoma6 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour3 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma6 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 淋巴瘤Lymphoma11 篇牵头论文牵头 1 项开放试验
- 冠心病Coronary heart disease5 篇牵头论文
未列出的收录疾病:胰腺癌、乳腺癌、脊索瘤、尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 2 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文20
- Paclitaxel/Luteolin Coloaded Dual-Functional Liposomes for Esophageal Cancer Therapy.
- Chemoradiotherapy with or Without Anlotinib for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: A Real-World Observational Study.
- Prognostic value of the ARISCAT score for postoperative pneumonia in patients with esophageal squamous cell carcinoma: a retrospective cohort study.
- HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4-ERK1/2-U2AF2-TFRC axis.
- Impact of Dietary Behavioural Changes on Prognosis of Postoperative Oesophageal Squamous Cell Carcinoma Patients: A Retrospective Cohort Study.
- CT-radiomics combined with inflammatory indicators for prediction of progression free survival of resectable esophageal squamous cell carcinoma.
- Predicting the Efficacy of Neoadjuvant Chemotherapy Combined with Immunotherapy for Esophageal Squamous Cell Carcinoma via Enhanced CT Radiomics Combined with Clinical Features.
- The predictive role of PNI and NRS2002 for postoperative pulmonary complications in ESCC patients undergoing neoadjuvant chemoimmunotherapy followed by McKeown esophagectomy: a retrospective cohort study.
- Consensus Clustering Analysis Based on Enhanced-CT Radiomic Features: Esophageal Squamous Cell Carcinoma patients' 3-Year Progression-Free Survival.
- Development of a Specific Aptamer-Modified Nano-System to Treat Esophageal Squamous Cell Carcinoma.
- Examining the relationship between preoperative nutritional and symptom assessment and postoperative atrial fibrillation in esophageal squamous cell carcinoma patients: a retrospective cohort study.
- hOGG1: A novel mediator in nitrosamine-induced esophageal tumorigenesis.
- FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring exosomal lncRNA AFAP1-AS1.
- Single-Cell Transcriptomics Reveals STAT1 Drives LHPP Downregulation in Esophageal Squamous Cell Carcinoma Progression.
- A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker.
- Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.
- LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
- ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.
- Self-assembled RNA nanocarrier-mediated chemotherapy combined with molecular targeting in the treatment of esophageal squamous cell carcinoma.
- Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus
- Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
- Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)10
- Construction of a egg yolk lipid-based co-delivery nano-drug system targeting PDPN and its in vitro anti-esophageal squamous cell carcinoma effects
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study
- Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.
- Retrospective study of continued immunotherapy in patients with advanced esophageal squamous cell carcinoma after progression on first-line immunotherapy combination chemotherapy.
- 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
- Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway
- Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway
- Cholinergic signals promote esophageal squamous cell carcinoma metastasis by activating EGFR/AKT signaling pathway
- ASO Visual Abstract: Additional esophagectomy following noncurative endoscopic resection for early esophageal squamous cell carcinoma: a multicenter retrospective study
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.04%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification.
- Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging.
- Interference of EFNA4 suppresses cell proliferation, invasion and angiogenesis in hepatocellular carcinoma by downregulating PYGO2.
- Curcumin restrains hepatocellular carcinoma progression depending on the regulation of the circ_0078710/miR-378b/PRIM2 axis.
- TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates beta-catenin/TCF signalling.
- Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在胃癌下全国有 211 家医院列在胃癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文13
- Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study.
- Ligation-assisted endoscopic full-thickness resection combined with preloaded sutures for tiny mesenchymal tumors of the gastric fundus.
- Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p.
- Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy.
- Metastatic breast carcinoma and Krukenberg tumor from signet-ring cell gastric cancer.
- Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor.
- Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.
- Knockdown of mediator complex subunit 27 suppresses gastric cancer cell metastasis and angiogenesis via Wnt/β-catenin pathway.
- MiRNA-621 exerts tumor suppressor function in gastric adenocarcinoma by targeting AURKA/GSK-3β pathway.
- RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
- DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290.
- Integrated bioinformatics analysis for differentially expressed genes and signaling pathways identification in gastric cancer.
- NUPR1 participates in YAP-mediate gastric cancer malignancy and drug resistance via AKT and p21 activation.
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.08%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在肺癌下全国有 251 家医院列在肺癌下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的肺癌开放试验。
这些数字背后的记录
牵头的论文19
- RFWD3 Knockdown Inhibits Cancer Cell Proliferation, Migration, and Invasion while Promoting Apoptosis of Non-Small Cell Lung Cancer Cells.
- Immunological biomarkers and gene signatures predictive of radiotherapy resistance in non-small cell lung cancer.
- Predicting Gene Comutation of EGFR and TP53 by Radiomics and Deep Learning in Patients With Lung Adenocarcinomas.
- Retrospective comparative study of thoracoscopic lobectomy vs. segmentectomy: Enhancing recovery and lung function in early-stage non-small cell lung cancer.
- CENPF Upregulation is Associated with Immunosuppressive Status and Poor Clinical Outcomes in Lung Adenocarcinoma Validated by qRT-PCR.
- Predicting visceral pleural invasion in lung adenocarcinoma presenting as part-solid density utilizing a nomogram model combined with radiomics and clinical features.
- Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.
- Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.
- Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
- High‑risk pathological subtype associated FAM83A‑AS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR‑202‑3p/HK2 axis.
- Comparison and fusion prediction model for lung adenocarcinoma with micropapillary and solid pattern using clinicoradiographic, radiomics and deep learning features.
- Developing and validating a prediction model for in-hospital mortality in patients with ventilator-associated pneumonia in the ICU.
- CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
- SOX2 como posible biomarcador pronóstico y diana molecular en el cáncer de pulmón: metaanálisis.
- Ultrasound-Guided Thoracic Paravertebral Nerve Block on Postoperative Pain, Quality of Life, and Recovery in Patients with Non-Small-Cell Lung Cancer.
- RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
- MicroRNA miR-19b-3p mediated G protein γ subunit 7 (GNG7) loss contributes lung adenocarcinoma progression through activating Hedgehog signaling.
- Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis.
- Prediction efficacy of feature classification of solitary pulmonary nodules based on CT radiomics.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.07%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。
这些数字背后的记录
牵头的论文5
- Causes of death among patients with primary malignant brain tumors in the US from 2000 to 2021.
- Targeted therapy for glioblastoma utilizing hyaluronic acid-engineered liposomes for adriamycin delivery.
- DBX2 Promotes Glioblastoma Cell Proliferation by Regulating REST Expression.
- ITPRIP promotes glioma progression by linking MYL9 to DAPK1 inhibition.
- Positioning error analysis of the fraxion localization system in the intracranial stereotactic radiotherapy of tumors.
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- MicroRNA-708 suppresses the proliferation, migration, and invasion of human retinoblastoma cells by targeting RAP2B, a member of the RAS oncogene family.
- Long Non-coding RNA FEZF1-AS1 Promotes Growth and Reduces Apoptosis Through Regulation of miR-363-3p/PAX6 Axis in Retinoblastoma.
- MiR-146a functions as a potential tumor suppressor in retinoblastoma by negatively regulate neuro-oncological ventral antigen-1.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- Nanoparticles-encapsulated doxorubicin alleviates drug resistance of osteosarcoma via inducing ferroptosis.
- ALOX5AP suppresses osteosarcoma progression via Wnt/β-catenin/EMT pathway and associates with clinical prognosis and immune infiltration.
- Circular RNA circ_0002137 regulated the progression of osteosarcoma through regulating miR-433-3p/ IGF1R axis.
- Expression level of PLAC1 in osteosarcoma patients and its regulatory effect on the development of osteosarcoma.
- The circular RNA circCRIM1 inhibits osteosarcoma progression through sponging miR-513.
- Depletion of circRNA circ_CDK14 inhibits osteosarcoma progression by regulating the miR-520a-3p/GAB1 axis.
早期论文(2016–2020 年)12
- MicroR-542-3p can mediate ILK and further inhibit cell proliferation, migration and invasion in osteosarcoma cells.
- SP1-mediated upregulation of lncRNA ILF3-AS1 functions a ceRNA for miR-212 to contribute to osteosarcoma progression via modulation of SOX5.
- Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma.
- Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223.
- Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma.
- LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling.
- miR‑590‑5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5.
- Identification of Key Gene Modules in Human Osteosarcoma by Co-Expression Analysis Weighted Gene Co-Expression Network Analysis (WGCNA).
- Folic acid-tagged titanium dioxide nanoparticles for enhanced anticancer effect in osteosarcoma cells.
- Assessment of GSK1904529A as a promising anti-osteosarcoma agent.
- RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1.
- Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文3
- Ligation-assisted endoscopic full-thickness resection combined with preloaded sutures for tiny mesenchymal tumors of the gastric fundus.
- Interpretable machine learning model based on CT semantic features and radiomics features to preoperatively predict Ki-67 expression in gastrointestinal stromal tumors.
- Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。
这些数字背后的记录
牵头的论文6
- The prognostic value of POD24 for multiple myeloma: a comprehensive analysis based on traditional statistics and machine learning.
- NPM1 mediated up - regulation of CXCR4 might drive bortezomib resistance in multiple Myeloma.
- The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen.
- An evolutionary machine learning for multiple myeloma using Runge Kutta Optimizer from multi characteristic indexes.
- Prognostic role of controlling nutritional status score in hematological malignancies.
- Research progress on treatment of extramedullary multiple myeloma.
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
淮安有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.3%。
淮安有 1 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
- 分期
- II期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06566807
年龄 18 岁 至 未注明(登记的条件)
牵头:淮安市第一人民医院淮安
- 正在招募ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- 分期
- II/III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06378138
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、宜昌、广州、成都、杭州、武汉、沈阳、洛阳、济南、淮安、石家庄、福州、蚌埠、西安、遵义、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Prognostic significance of CDK1 expression in diffuse large B-Cell lymphoma.
- Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity.
- Global, regional, and national burden of Hodgkin lymphoma, 1990-2021, and predictions for 2050: an analysis of the global burden of disease study 2021.
- CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling.
- Cathepsins effect on diffuse large B cell lymphoma risk: A Mendelian randomization study.
- Development and validation of prognostic models based on 18F-FDG PET radiomics, metabolic parameters, and clinical factors for elderly DLBCL patients.
- Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma.
- The association of COVID-19 with diffuse large B-cell lymphoma: a Mendelian randomization study.
- The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma.
- The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study.
- ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
- A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Obinutuzumab in Chinese Real-world Patients With iNHL
- Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
- A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
- Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
淮安有 1 家医院列在冠心病下全国有 231 家医院列在冠心病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- 分期
- 不分期
- 开始
- 2021-09
- 发布
- 登记号
- NCT04995159
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Preoperative hemoglobin predicts clinical outcomes after percutaneous coronary intervention.
- TRAF3IP2 as a novel inflammatory biomarker for coronary artery disease: development and validation of a multimodal prediction model.
- The incremental value of CCTA-derived myocardial radiomics signature for ischemia diagnosis with reference to CT myocardial perfusion imaging.
- Serum miR-96-5p is a novel and non-invasive marker of acute myocardial infarction associated with coronary artery disease.
- Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients
- Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
联系这家医院
出示给工作人员或司机的院名卡
淮安市第一人民医院
Huai'an First People's Hospital
淮安
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药